This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Dermatology  • Dermatologic Disorders  • Bullous Diseases  • Neoplasms  • Pemphigoid  • Dermatologic Disorders, Other  • Drug Therapy  • Drug Therapy, Other  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jennifer M. Gardner, MD; Katherine G. Evans, MD; Steven Goldstein, MD; Ellen J. Kim, MD; Carmela C. Vittorio, MD; Alain H. Rook, MD

Arch Dermatol. 2009;145(9):985-988.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Histone deacetylase (HDAC) inhibitors represent a novel class of medication that is being targeted for use in the treatment of cancer. A member of this class, vorinostat, has recently been approved for the therapy of cutaneous T-cell lymphoma. Importantly, emerging data from animal studies have indicated that HDAC inhibitors may have the capacity to potently suppress the development of autoimmune disease. In this report, we describe a patient with advanced cutaneous T-cell lymphoma who developed refractory bullous pemphigoid (BP) and then experienced the rapid resolution of the BP following initiation of treatment with vorinostat. This observation may be broadly applicable to the treatment of other autoimmune skin diseases.

REPORT OF A CASE

Our patient, a 59-year-old woman, was diagnosed in 1996 as having mycosis fungoides/cutaneous T-cell lymphoma (MF/CTCL), stage IB, with . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT

AUTHOR INFORMATION

Department of Dermatology, University of Pennsylvania Health System, Philadelphia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?